anagrelide

(redirected from Agrelin)

anagrelide

 [an-ag´rĕ-līd]
an agent used in the form of the hydrochloride salt to reduce elevated platelet counts and the risk of thrombosis in treatment of hemorrhagic thrombocythemia; administered orally.

anagrelide

/an·ag·re·lide/ (an-ag´rĕ-līd) an agent used to reduce elevated platelet counts and the risk of thrombosis in the treatment of hemorrhagic thrombocythemia; used as the hydrochloride salt.

anagrelide

an antiplatelet agent.
indication This drug is prescribed for essential thrombocythemia.
contraindications Known hypersensitivity and hypotension prohibit its use.
adverse effects Life-threatening effects include congestive heart failure, myocardial infarction, myocardiopathy, cardiomegaly, complete heart block, atrial fibrillation, anemia, thrombocytopenia, ecchymosis, and lymphadenoma. Other serious effects include tachycardia, palpitations, arrhythmia, and seizures. Common side effects include orthostatic hypotension and rash.

anagrelide

A cytoreductive agent used to manage essential thrombocythaemia and thrombocythaemia due to myeloproliferative disorders (e.g., CML, polycythemia vera) to reduce platelets, risk of thrombosis and other symptoms. It is generally regarded as a second-line therapy compared to hydroxyurea.

Anagrelide

An orphan drug that is approved for treating PV patients on an investigational basis. Anagrelide works by controlling the level of platelets in the blood.
Mentioned in: Polycythemia Vera
References in periodicals archive ?
Patent and Trademark Office for improved methods for the chemical synthesis of anagrelide, the active ingredient in AGRELIN (R).
Published studies confirm that AGRELIN reduces the morbidity and mortality of heart attack and stroke in thrombocytosis patients.
3 million as a result of a reduced level of expenditure required to support the Company's development program for Agrelin.
Vukovich, Chairman and CEO of Roberts, commented on the financial performance of the Company by stating, "Roberts has achieved six straight quarters of profits while continuing to fund a significant level of R&D activity in support of our ongoing effort to obtain FDA approval for AMATINE, for hypotension, AGRELIN, for excessive platelet production, and MAXIVENT, an oral bronchodilator.
April 19 /PRNewswire/ -- Roberts Pharmaceutical Corporation (NASDAQ: RPCX) announced today that it has entered into a distribution arrangement with Swedish Orphan AB for the distribution and sale of AGRELIN in the Nordic Countries of Norway, Sweden, Finland, Denmark and Iceland.
AGRELIN is not yet approved in the Nordic Countries and, as part of the agreement with Roberts, Swedish Orphan is responsible for obtaining regulatory approval.
MARCH 30 -- Roberts Pharmaceutical Corporation (NASDAQ-NMS: RPCX) announced today that it has signed a letter of intent with the Italian pharmaceutical company, Inverni della Beffa of Milan, for the marketing and sale of AGRELIN in Italy.
Inverni della Beffa will prepare and prosecute a health registration application for AGRELIN in Italy in conjunction with Roberts efforts to obtain EEC-wide approval using the concertation procedure (CPMP).
In NY048, Roberts Pharmaceutical Corporation To Award Marketing Rights For Agrelin Anti-Platelet Drug To Italian Firm, moved earlier today; and in NY048A, Correction to Roberts Pharmaceutical, also moved earlier today, we are advised by a representative of the company that the contact phone number for Anthony P.
March 16 /PRNewswire/ -- Roberts Pharmaceutical Corporation (NASDAQ-NMS: RPCX) reported today that their antiplatelet drug, AGRELIN (anagrelide hydrochloride), has been accepted by the European Community (EC) regulatory authorities as a "List B" product.
AGRELIN is a drug used to lower excessively high platelet counts in patients diagnosed with hyperplastic bone marrow diseases such as essential thrombocythemia or chronic myelogenous leukemia.